WO1998005770A3 - Antisense rna with a secondary structure - Google Patents

Antisense rna with a secondary structure Download PDF

Info

Publication number
WO1998005770A3
WO1998005770A3 PCT/DE1997/001691 DE9701691W WO9805770A3 WO 1998005770 A3 WO1998005770 A3 WO 1998005770A3 DE 9701691 W DE9701691 W DE 9701691W WO 9805770 A3 WO9805770 A3 WO 9805770A3
Authority
WO
WIPO (PCT)
Prior art keywords
antisense rna
secondary structure
combination
rnase
disclosed
Prior art date
Application number
PCT/DE1997/001691
Other languages
German (de)
French (fr)
Other versions
WO1998005770A2 (en
Inventor
Dieter Werner
Christof Granzow
Gaby Joswig
Karsten Rothbarth
Marie Schubert
Original Assignee
Deutches Krebsforschungszentru
Dieter Werner
Christof Granzow
Gaby Joswig
Karsten Rothbarth
Marie Schubert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutches Krebsforschungszentru, Dieter Werner, Christof Granzow, Gaby Joswig, Karsten Rothbarth, Marie Schubert filed Critical Deutches Krebsforschungszentru
Priority to EP97936610A priority Critical patent/EP0918853A2/en
Publication of WO1998005770A2 publication Critical patent/WO1998005770A2/en
Publication of WO1998005770A3 publication Critical patent/WO1998005770A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01028—Chloramphenicol O-acetyltransferase (2.3.1.28)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

An antisense RNA with special secondary structures is disclosed, as well as a combination of the antisense RNA and of a (ds)RNAse. The antisense RNA and its combination may be used to inhibit gene expression.
PCT/DE1997/001691 1996-08-07 1997-08-05 Antisense rna with a secondary structure WO1998005770A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97936610A EP0918853A2 (en) 1996-08-07 1997-08-05 Antisense rna with a secondary structure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19631919.6 1996-08-07
DE1996131919 DE19631919C2 (en) 1996-08-07 1996-08-07 Anti-sense RNA with secondary structure

Publications (2)

Publication Number Publication Date
WO1998005770A2 WO1998005770A2 (en) 1998-02-12
WO1998005770A3 true WO1998005770A3 (en) 1998-03-26

Family

ID=7802056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/001691 WO1998005770A2 (en) 1996-08-07 1997-08-05 Antisense rna with a secondary structure

Country Status (3)

Country Link
EP (1) EP0918853A2 (en)
DE (1) DE19631919C2 (en)
WO (1) WO1998005770A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8101742B2 (en) 1999-01-30 2012-01-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA
US9422564B2 (en) 2002-12-23 2016-08-23 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US9587240B2 (en) 2001-01-09 2017-03-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR101085210B1 (en) 1998-03-20 2011-11-21 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US8598332B1 (en) 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
JP5015373B2 (en) * 1998-04-08 2012-08-29 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Methods and means for obtaining an improved phenotype
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
BR0013607A (en) 1999-08-26 2002-04-30 Calgene Llc Nucleic acid sequences and processes of use for the production of plants with modified polyunsaturated fatty acids
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (en) * 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
DE10100586C1 (en) * 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
CA2404890C (en) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
BRPI0115814B8 (en) 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl double-stranded RNA molecules, their method of preparation and pharmaceutical composition comprising them
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
WO2003035083A1 (en) * 2001-10-26 2003-05-01 Ribopharma Ag Drug for treating a fibrotic disease through rna interfence
BR0308424A (en) 2002-03-14 2005-02-22 Commw Scient Ind Res Org Methods and means for efficiently downregulating the expression of any gene of interest in eukaryotic cells and organisms
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
EP1484959A4 (en) 2002-03-21 2005-08-31 Monsanto Technology Llc Nucleic acid constructs and methods for producing altered seed oil compositions
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
SI3222724T1 (en) 2002-08-05 2019-03-29 Silence Therapeutics Gmbh Further novel forms of interfering rna molecules
US7078234B2 (en) 2002-12-18 2006-07-18 Monsanto Technology Llc Maize embryo-specific promoter compositions and methods for use thereof
SI1575977T1 (en) * 2002-12-23 2010-01-29 Dynavax Tech Corp Immunostimulatory sequence oligonucleotides and methods of using the same
CN1836045B (en) 2003-03-28 2012-05-09 孟山都技术有限公司 Novel plant promoters for use in early seed development
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
US20060021087A1 (en) 2004-04-09 2006-01-26 Baum James A Compositions and methods for control of insect infestations in plants
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
EP2489726A3 (en) 2005-01-12 2012-11-28 Monsanto Technology LLC Genes and uses for plant improvement
ATE552343T1 (en) 2005-04-19 2012-04-15 Basf Plant Science Gmbh ENDOSPERM-SPECIFIC EXPRESSION AND/OR EXPRESSION IN GERMINATING EMBRYOS OF MONOCOTYLEDONE PLANTS
PL2431473T3 (en) 2005-09-16 2017-05-31 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
CA2622671C (en) 2005-09-16 2020-12-22 Devgen Nv Methods for controlling pests using rnai
CA2622660C (en) 2005-09-16 2017-11-07 Devgen Nv Transgenic plant-based methods for plant pests using rnai
BRPI0707626A2 (en) 2006-02-10 2011-05-10 Monsanto Technology Llc identification and use of target genes for the control of plant parasitic nematodes
CA2836368C (en) 2006-02-13 2020-04-07 Monsanto Technology Llc Method for managing crop pest resistance
CN101421406B (en) 2006-02-13 2016-08-31 孟山都技术有限公司 For producing nucleic acid construct and the method that the seed oil of change forms
CN101195821A (en) 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 Method for improving insect resistance of plant by using RNAi technique
CA2675926A1 (en) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US8329989B2 (en) 2008-09-29 2012-12-11 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
MX2011011076A (en) 2009-04-20 2011-11-18 Monsanto Technology Llc Multiple virus resistance in plants.
EP3354735A1 (en) 2010-12-30 2018-08-01 Dow AgroSciences LLC Nucleic acid molecules that target the rho1 small gtp-binding protein and confer resistance to coleopteran pests
UY33851A (en) 2010-12-30 2012-07-31 Dow Agrosciences Llc NUCLEIC ACID MOLECULES THAT CONFERENCE RESISTANCE TO COLEOPTER PESTS
BRPI1107329A2 (en) 2010-12-30 2019-11-19 Dow Agrosciences Llc nucleic acid molecules that target the vacuolar atpase h-subunit that confer resistance to Coleoptera pests, plant transformation vector, transformed cell, as well as methods for controlling a Coleoptera pest population, controlling an infestation by said pest, improving the yield of a crop and to produce a transgenic cell
BRPI1107332A2 (en) 2010-12-30 2018-10-30 Dow Agrosciences Llc polynucleotide, transformation vector, nucleic acid molecules, cell, as well as methods for coleopteran pest control, for enhancement of maize crop yield, and for production of coleopteran pest resistant cell and plant
US9688983B2 (en) 2012-12-20 2017-06-27 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
MX2016008263A (en) 2013-12-20 2017-05-09 Dow Agrosciences Llc Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests.
BR102014031844A2 (en) 2013-12-20 2015-10-06 Dow Agrosciences Llc RAS and related nucleic acid molecules that confer resistance to Coleoptera and Hemiptera pests
MX366975B (en) 2014-03-12 2019-08-01 Univ Sydney Rna production in higher plants.
AU2015255995B2 (en) 2014-05-07 2018-05-10 Dow Agrosciences Llc Dre4 nucleic acid molecules that confer resistance to coleopteran pests
US20160194658A1 (en) 2014-12-22 2016-07-07 Dow Agrosciences Llc Nucampholin nucleic acid molecules to control coleopteran insect pests
EP3067424A1 (en) 2015-03-13 2016-09-14 Dow AgroSciences LLC Rna polymerase i1 nucleic acid molecules to control insect pests
US20180105832A1 (en) 2015-04-13 2018-04-19 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel aflatoxin and fungal infection control methods
BR102016012010A2 (en) 2015-05-29 2020-03-24 Dow Agrosciences Llc NUCLEIC ACID, RIBONUCLEIC ACID (RNA) AND DOUBLE-FILAMENT RIBONUCLEIC ACID (DSRNA) MOLECULE, CELL, PLANT AND SEED USES, PRIMARY PRODUCT, AS WELL AS METHODS TO CONTROL A POPULATION OF HOLIDAYS, OR HOSPITALS, OR HOSPITALS, OR HOSPITALS, OR HOSPITALS THE INCOME OF A CULTURE, AND TO PRODUCE A TRANSGENIC VEGETABLE CELL AND A TRANSGENIC PLANT
CN108431207A (en) 2015-10-12 2018-08-21 美国陶氏益农公司 Assign the WUPA nucleic acid molecules to the resistance of coleoptera and Hemipteran pest
AU2016371636A1 (en) 2015-12-18 2018-06-21 Dow Agrosciences Llc Ribosomal protein L40 (RPL40) nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
WO2018089237A1 (en) 2016-11-10 2018-05-17 Dow Agrosciences Llc Cytochrome b (cytb) nucleic acid molecules that control pathogens
EP3342780A1 (en) 2016-12-30 2018-07-04 Dow AgroSciences LLC Pre-mrna processing factor 8 (prp8) nucleic acid molecules to control insect pests
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019732A1 (en) * 1991-04-25 1992-11-12 Genset Closed sense and antisense oligonucleotides and uses thereof
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
EP0592685A1 (en) * 1992-04-17 1994-04-20 Kirin Beer Kabushiki Kaisha Plant resistant to two or more viruses and preparation thereof
WO1994023026A1 (en) * 1993-03-26 1994-10-13 Genset Staple and semi-staple oligonucleotides, method of preparation and applications
WO1995010607A1 (en) * 1993-10-14 1995-04-20 The Regents Of The University Of California Antisense oligonucleotide generators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019732A1 (en) * 1991-04-25 1992-11-12 Genset Closed sense and antisense oligonucleotides and uses thereof
EP0592685A1 (en) * 1992-04-17 1994-04-20 Kirin Beer Kabushiki Kaisha Plant resistant to two or more viruses and preparation thereof
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
WO1994023026A1 (en) * 1993-03-26 1994-10-13 Genset Staple and semi-staple oligonucleotides, method of preparation and applications
WO1995010607A1 (en) * 1993-10-14 1995-04-20 The Regents Of The University Of California Antisense oligonucleotide generators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HELENE C ET AL: "LA STRATEGIE ANTISENS: NOUVELLES APPROCHES THERAPEUTIQUES", MEDECINE SCIENCES, vol. 10, no. 3, 1 March 1994 (1994-03-01), pages 253 - 273, XP000576223 *
NELLEN, W. & LICHTENSTEIN, C.: "WHAT MAKES AN MESSENGER-RNA ANTI-SENSE-ITIVE ?", TRENDS IN BIOCHEMICAL SCIENCES, (NOV 1993) VOL. 18, NO. 11, PP. 419-423., XP002049385 *
ROTONDO, G. & FRENDEWEY, D.: "PURIFICATION AND CHARACTERIZATION OF THE PAC1 RIBONUCLEASE OF SCHIZOSACCHAROMYCES-POMBE", NUCLEIC ACIDS RESEARCH, (15 JUN 1996) VOL. 24, NO. 12, PP. 2377-2386., XP002049388 *
URATA, H. ET AL.: "NMR study of a heterochiral DNA: stable Watson-Crick-type base-pairing between the enantiomeric residues", J. AM. CHEM. SOC. (1993), 115, 9852-3, XP002052970 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8148345B2 (en) 1999-01-28 2012-04-03 Georgia Health Sciences University Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8101742B2 (en) 1999-01-30 2012-01-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US8101584B2 (en) 1999-01-30 2012-01-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US8114981B2 (en) 1999-01-30 2012-02-14 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US8114851B2 (en) 1999-01-30 2012-02-14 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US8168776B2 (en) 1999-01-30 2012-05-01 Alnylam Pharmaceuticals, Inc. Method for making a 21 nucleotide double stranded RNA chemically linked at one end
US8183362B2 (en) 1999-01-30 2012-05-22 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US8729037B2 (en) 1999-01-30 2014-05-20 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US9587240B2 (en) 2001-01-09 2017-03-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA
US9422564B2 (en) 2002-12-23 2016-08-23 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same

Also Published As

Publication number Publication date
WO1998005770A2 (en) 1998-02-12
DE19631919C2 (en) 1998-07-16
DE19631919A1 (en) 1998-02-12
EP0918853A2 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
WO1998005770A3 (en) Antisense rna with a secondary structure
AU5101398A (en) Inhibiting hiv infection by cleaving co-receptor rna
AU6452294A (en) Dinucleotide analogues, intermediates therefor and oligonucleotides derived therefrom
AU2002216657A1 (en) One-piece closed-shape structure and method of forming same
CA2359180A1 (en) Method and medicament for inhibiting the expression of a given gene
AU2001278415A1 (en) Alpha-amylase mutants with altered stability
WO2000054080A3 (en) Aperiodic longitudinal gratings and optimisation method
AU2707399A (en) Configuration knowledge as an aid to case retrieval
ZA200104181B (en) Small diameter can end with large opening.
WO2000046383A3 (en) Method of modulating metabolite biosynthesis in recombinant cells
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
AU2001273327A1 (en) Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
AU5694901A (en) Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
WO2001054211A3 (en) Air recovery battery
AU7012398A (en) Object, above all a personal object to be worn by an individual and/or n objectassociated to a specific object, as part of a data transmission system
WO2001034951A3 (en) A gas sensor terminal assembly and method of producing same
AU2001296414A1 (en) Tungsten-containing fuel cell catalyst and method of making same
AU2764497A (en) Alpha-glucuronidases of aspergillus, production thereof and their uses
AU4944693A (en) New xylanases having high activity and stability at alkaline conditions and high temperatures
AU2002226064A1 (en) Antisense modulation of talin expression
AU1067199A (en) Isolation and expression of farnesene synthase from peppermint, mentha x piperita, L.
AU5485398A (en) Method for increasing the efficiency of photoelectro-chemical cells, and photoelectro-chemical cells realized according to said method
WO2002077184A3 (en) Oligonucleotide conjugates
AU2568697A (en) An enzyme with beta-1,3-glucanase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997936610

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09230930

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997936610

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998507488

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1997936610

Country of ref document: EP